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674Acute Kidney Injury in Patients with Systemic Sclerosis
Participating in Hematopoietic Cell Transplantation
Trials in the United States
Chitra Hosing,1 Richard Nash,2 Peter McSweeney,3 Shin Mineishi,4
James Seibold,5 Linda M. Griffith,6 Howard Shulman,7 Ellen Goldmuntz,8
Maureen Mayes,9 Chirag R. Parikh,10 Leslie Crofford,11 Lynette Keyes-Elstein,12
Daniel Furst,13 Virginia Steen,14 Keith M. Sullivan15Recipients of hematopoietic cell transplantationmay be at risk for developing acute kidney injury (AKI), and this
risk may be increased in patients who undergo transplantation for severe systemic sclerosis (SSc) due to under-
lying scleroderma renal disease. AKI after transplantation can increase treatment-related mortality. To better
define these risks, we analyzed 91 patients with SSc who were enrolled in 3 clinical trials in the United States
of autologous or allogeneic hematopoietic cell transplantation (HCT). Eleven (12%) of the 91 patients with
SSc in these studies (8 undergoing autologous HCT, 1 undergoing allogeneic HCT, 1 pretransplantation, 1 given
i.v. cyclophosphamide on a transplantation trial) experiencedAKI, of whom8 required dialysis and/or therapeu-
tic plasma exchange. AKI injury in the 9 HCTrecipients developed a median of 35 days (range, 0-90 days) after
transplantation. Ten of 11 patients with AKI received angiotensin-converting enzyme inhibitor (ACE-I) therapy.
The etiology of AKIwas attributed to scleroderma renal crisis in 6 patients (including 2with normotensive renal
crisis), to AKI of uncertain etiology in 2 patients, and to AKI superimposed on scleroderma kidney disease in 3
patients. Eight of the 11patients died, one each becauseof progression of SSc,multiorgan failure, gastrointestinal
and pulmonary bleeding, pericardial tamponade and pulmonary complications, diffuse alveolar hemorrhage,
pulmonary embolism, graft-versus-host disease, and malignancy. Limiting nephrotoxins, cautious use of
corticosteroids, renal shielding during total body irradiation, strict control of blood pressure, and aggressive
use of ACE-Is may be of importance in preventing renal complications after HCT for SSc.
Biol BloodMarrowTransplant 17: 674-681 (2011) 2011American Society for Blood andMarrowTransplantation. Published
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Acute kidney injury (AKI) has been reported inup to
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Table 1. Classification/Staging System for AKI*
Stage Serum Creatinine Criteria Urine Output Criteria
1 Increase in serum creatinine of $0.3 mg/dL ($26.4 mmol/L) or
increase to $150% to 200% (1.5- to 2-fold) from baseline
Less than 0.5 mL/kg per hour for more than 6 hours
2† Increase in serum creatinine to >200% to 300% (>2- to 3-fold) from
baseline
Less than 0.5 mL/kg per hour for more than 12 hours
3‡ Increase in serum creatinine to >300% (>3-fold) from baseline (or
serum creatinine ofmore than or equal to 4.0 mg/dL [$354 mmol/L]
with an acute increase of at least 0.5 mg/dL [44 mmol/L])
Less than 0.3 mL/kg per hour for 24 hours
or anuria for 12 hours
Modified from RIFLE (risk, injury, failure, loss, and end-stage kidney disease) criteria [51]. The proposed staging system is a highly sensitive interim staging
system and is based on recent data indicating that a small change in serum creatinine influences outcome. Only one criterion (creatinine or urine output)
must be fulfilled to qualify for a stage.
*Adapted from Mehta et al. 2007 [13].
†A 200%-300% increase 5 a 2- to 3-fold increase.
‡Given the wide variation in indications and timing of initiation of renal replacement therapy (RRT), individuals who receive RRTare considered to have
met the criteria for stage 3, regardless of the stage at the time of RRT.
Biol Blood Marrow Transplant 17:674-681, 2011 675Acute Kidney Injury in Patients with Systemic Sclerosistransplantation [4-8]. The degree of renal impairment
posttransplantation has been shown to impact the
mortality rate [9]; therefore, patients with SSc who re-
ceive high-dose immunosuppression followed by autol-
ogous or allogeneic HCT may be at increased risk for
developing renal complications. In a pilot study of
lymphoablation with a total body irradiation (TBI)-
containing regimen followed byCD341 selected autol-
ogous HCT in patients with severe SSc, dramatic
improvement/resolution of dermal fibrosis and stabiliza-
tion/improvement of pulmonary function was observed;
however, 6 of the 34 patients (18%) developed AKI [10].
This report characterizes renal complications and
outcomes observed in patients with poor-prognosis
SSc (diffuse cutaneous disease with internal organ in-
volvement) who participated in 3 clinical trials of
HCT in the United States, and offers guidelines for
prevention of AKI. The subjects described in this re-
port are derived from the pilot study of high-dose ther-
apy and autologous HCT (34 subjects), the ongoing
randomized study of chemotherapy versus autologous
HCT in the SCOT (Scleroderma Cyclophosphamide
or Transplantation) trial (55 subjects randomized to
date), and a study of allogeneic HCT (2 subjects).PATIENTS AND METHODS
From the two published studies, we identified pa-
tients with severe SScwho developed AKI after undergo-
ing autologous or allogeneic HCT [10,11]. We also
identified subjects with AKI among those randomized
to date on the SCOT study (www.sclerodermatrial.org).
Subjects on the SCOT protocol are randomized to 12
monthly i.v. infusions of 750 mg/m2 cyclophosphamide
(Cy) or to myeloablative conditioning followed by
CD341 selected autologous HCT. The subjects
undergoing autologous HCT received conditioning
with 120 mg/kg Cy, 90 mg/kg antithymocyte globulin
(ATGAM), and 800 cGy TBI. TBI was given in four
200-cGy fractions over 2 days, with lung shielding to
200 cGy pulmonary transmission. Subjects enrolled onthe SCOT trial also received kidney shielding to 200
cGy renal transmission [12]. Patients given ATGAM re-
ceived methylprednisolone 0.5 mg/kg/day from day 16
through day 121 posttransplantation and then tapered
throughday137, to reduceallergic reactions toATGAM
and damage to organs. The allogeneic HCT recipients
received conditioning ATGAM, busulfan, and Cy, fol-
lowed by cyclosporine and methotrexate for graft-
versus-host disease (GVHD) prophylaxis [11].
AKI was defined as an abrupt (within 48 hours) re-
duction in kidney function, as measured by an absolute
increase in serum creatinine of $0.3 mg/dL or
a percentage increase in serum creatinine of $150%
(1.5-fold) from baseline. Information on urine output
was not available [13]. Staging of AKI is detailed in
Table 1. Results were analyzed as of August 4, 2009.
All patients participating in these trials gave informed
consent in accordance with local institutional review
board standards.RESULTS
A total of 34 individuals with SSc were enrolled in
the pilot study of autologous HCT [10]. To date, the
SCOT trial has randomized 28 patients to SCT and
27 patients to monthly i.v. Cy. The third study in-
cluded 2 patients who underwent allogeneic HCT
[11]. Of the 91 patients with severe SSc treated on
these 3 trials, 11 (12%) developed significant AKI.
Of the 64 patients who underwent allogeneic or autol-
ogous HCT, 9 (14%) developed AKI. Six of the 11 pa-
tients who developed AKI were on the pilot study of
autologous HCT, 4 were enrolled on the SCOT study
(1 patient randomized to the Cy arm, 1 patient who
underwent granulocyte-colony stimulating factor–
induced hematopoietic cell mobilization but did not
receive preparative conditioning or transplantation,
and 2 patients who received autologous HCT), and 1
patient received allogeneic HCT.
Table 2 presents characteristics of the 11 patients
who developed AKI. Patients 1-4 were from the
Table 2. Patient Characteristics
Patient Number 1 2 3 4 5 6 7 8 9 10 11
Study SCOT Randomized Study Allogeneic HCT Pilot Autologous HCT
Institution U Michigan Duke University MDACC UT Houston FHCRC FHCRC FHCRC Wayne State FHCRC FHCRC FHCRC
Age, years 52 43 60 59 31 50 43 42 47 41 53
Sex Male Male Female Female Female Female Female Female Female Male Male
Transplant type Autologous Autologous None (pre-
transplantation)
None (monthly
cyclophosphamide)
Allogeneic Autologous Autologous Autologous Autologous Autologous Autologous
Previous H/O SRC No No No Yes No No No No Yes No Yes
Day of onset of AKI (days from
transplantation)
D+6 D+23 NA NA D+39 D+24 D+44 D+85 +35 +90 0
Neurologic dysfunction No No Yes No Yes (seizures) No No No No No Yes (decreased level
of consciousness)
Hypertension Yes No Yes Yes Yes Yes Yes Yes Yes No No
Thrombocytopenia Yes* Yes Yes No Yes No† Yes (nadir
54,000)
Yes (nadir 7000) No No Yes*
LDH Normal High High NA High High High High Normal NA Normal
Coombs test ND Negative Negative ND ND ND ND ND ND NA ND
Schistocytes None Present None NA Few Moderate None Few Few NA None
Haptoglobin NA Low Normal ND Low ND ND ND ND NA Normal
Serum creatinine at
baseline, mg/dL
1.6 0.7 1.0 1.4 0.6 0.5 0.7 1.3 1.4 0.7 1.6
Maximum serum
creatinine, mg/dL
2.4 1.1 2.6 3.5 3.8 2.7 7.3 2.9 2.7 2.4 2.8
Absolute increase in
serum creatinine
over baseline,mg/dL
0.8 0.4 1.6 2.1 3.2 2.2 6.6 1.6 1.3 1.7 1.2
ACE-I Yes Yes Yes Yes Yes Started D+24 Yes Yes after diagnosis
of SRC
Yes No Yes
Hemodialysis Yes No Yes No Yes for volume Yes Yes Yes No No Yes
Plasma exchange No Yes  5 days Yes  3 days No No Yes No No No No No
Final diagnosis AKI Normotensive
SRC
AKI SRC SRC SRC AKI super-imposed
on SSc kidney
disease
SRC AKI super-
imposed
on SSc kidney
disease
Normotensive
SRC
AKI superimposed on
SSc kidney disease
Outcome Alive Alive Dead Dead Dead Dead Alive Dead Dead Dead Dead
Cause of death NA NA DAH Pulmonary
embolism
GVHD GI and pulmonary
bleeding
NA Pericardial effusion
(near tamponade),
pulmonary
complications
Disease
progression
at 5 years
Secondary
MDS/AML
Multiorgan failure
DAH indicates diffuse alveolar hemorrhage; ACE, angiotensin converting enzyme; FHCRC, Fred Hutchinson Cancer Research Center; LDH, lactate dehydrogenase; MDACC, M.D. Anderson Cancer Center; MDS/AML,
myelodysplastic syndrome/acute myelogenous leukemia; MOF, multiorgan failure; NA, not applicable; ND, not determined/available; UT, University of Texas.
Patient 1 remains on dialysis at last follow-up. Patient 3 was able to discontinue dialysis. Patient 5 underwent dialysis for a few days for volume control. Patient 6 discontinued dialysis for a while but then developed other
complications; she required dialysis again before her death. Patient 7 underwent dialysis for 21 months, and is now free from dialysis for 6 years. Patients 8 and 11 died while receiving dialysis.
*Posttransplantation.
†History of gastric antral vascular ectasia. The patient required platelet transfusions to maintain a platelet count >50  109 /L; she never became platelet transfusion–independent and died 6 months post-HCT.
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Figure 1. Periodic acid-Schiff–stained section of renal biopsy from pa-
tient 6. The glomerulus exhibits duplication of the basement membrane
(arrowhead), segmental collapse of capillary loops, and mesangiolysis.
An adjacent longitudinally oriented arteriole (arrow) has a small residual
eccentric lumen nearly obliterated by myointimal matrix. (Original mag-
nification, 40.)
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allogeneic HCT study, and patients 6-11 were from
the autologus HCT pilot study. All but one subject re-
ceived angiotensin-converting enzyme inhibitor
(ACE-I) therapy to prevent or treat SRC; patient 10
did not, because he was not hypertensive. After devel-
oping AKI, 3 patients underwent plasma exchange for
presumed diagnosis of transplantation-associated
thrombotic microangiopathy (TA-TMA)/thrombotic
thrombocytopenic purpura (TTP), and 7 patients re-
quired hemodialysis. The final diagnosis was SRC in
6 patients (normotensive SRC in 2), AKI of uncertain
etiology in 2 patients, and AKI superimposed on SRC
in 3 patients. The diagnosis was based on clinical and
laboratory data. Renal tissue was available for histo-
pathological evaluation in 2 patients (patients 6 and
8). At last follow-up, 3 of the 11 patients are alive, 1
of whom (patient 1) remains on dialysis. The survivingFigure 2. Autopsy kidney from patient 8 with SRC. (A) Interlobular arteriole
plasia. (Hematoxylin and eosin; original magnification, 40.) (B) The shrunken
endothelial cell (arrowhead). A contiguous afferent arteriole shows fibrinoid ne
original magnification, 40.)patients are 7, 31, and 72 months posttransplantation.
Two patients died while on dialysis. All others were
able to discontinue dialysis. Eight of the 11 patients
died, one each because of progression of SSc, multior-
gan failure, gastrointestinal and pulmonary bleeding,
pericardial tamponade and pulmonary complications,
diffuse alveolar hemorrhage, pulmonary embolism,
GVHD, and malignancy. None of these deaths was
directly attributable to AKI.
Figure 1 illustrates the renal pathology in patient 6.
Myointimal proliferation of arterioles and venules as
well as abnormalities in the glomerular capillaries,
including thickening and collapse of the walls and
widening of the subendothelial spaces, were seen.
Marked interstitial fibrosis associated with tubular
atrophy was present. Autopsy kidney sections from
patient 8 (Figure 2) showed widespread arterial and ar-
teriole myointimal thickening with mucoid degenera-
tion. The thickened myointimal layers within the
interlobular and afferent arterioles contained fibrinoid
material. There were multiple foci of segmental corti-
cal necrosis with sclerosis of glomeruli. Remaining
glomeruli showed a loss of capillary loops with necro-
sis of the endothelium. These vascular changes were
consistent with scleroderma vasculopathy. In addition,
there was interstitial fibrosis with tubular atrophy. The
kidney changes seen in patients 6 and 8 are consistent
with chronic kidney injury from severe SSc with some
superimposed changes of AKI.DISCUSSION
The etiology of AKI in HCT recipients is multifac-
torial and can be attributable to the effects of high-dose
chemotherapy, TBI, ATGAM, nephrotoxic drugs and
anti-infective agents, sepsis, hypotension, viral infec-
tion, TA-TMA, or i.v. contrast dyes used for imaging
studies. In allogeneic HCT recipients, this list expands
to include hepatic veno-occlusive disease and adminis-
tration of a calcineurin inhibitor (tacrolimus orwith severe luminal narrowing from ‘‘onion skin–like’’ myointimal hyper-
glomerulus exhibits a collapse of capillary loops with focal necrosis of
crosis (arrow) within the thickened intimal layer. (Hematoxylin and eosin;
678 Biol Blood Marrow Transplant 17:674-681, 2011C. Hosing et al.cyclosporine) for the prevention and treatment of
GVHD [14-18]. Development of AKI increases the
treatment-related mortality rate in both allogeneic and
autologous HCT [7,9]. Zager and coworkers [9] re-
ported that posttransplantation mortality increased
with worsening degree of renal impairment. In their
study, mortality exceeded 80% in patients who required
hemodialysis, and patients who survived were at an in-
creased risk for chronic kidney disease (CKD).
The incidence of AKI is frequently underestimated
in patients with SSc, because serum creatinine is a less-
robust marker of renal function in these patients, pre-
sumably because of renal vasculopathy and decreased
muscle mass resulting from scleroderma [19].
Whether or not the combination of SSc and HCT
magnifies the risk of subsequent renal complications
is unclear.
In a European phase I/II study of autologousHCT
in SSc, 5 of 41 patients (12%) were reported to have
scleroderma-related renal impairment before trans-
plantation, but only 1 of these patients experienced sig-
nificantly decreased serum creatinine level at 1 year
posttransplantation [20]. Although there was a 10%
rise in the final serum creatinine level over baseline,
the authors did not report a significant correlation be-
tween baseline renal function and survival [20]. Similar
results were noted by other European investigators,
who found that renal function remained stable after au-
tologous HCT for SSc [21,22]. Of note, most patients
who undergo transplantation for autoimmune disease
in Europe do not receive TBI for lymphoablation.
In the U.S. pilot trial of high-dose cyclophospha-
mide, ATGAM, TBI, and autologous HCT, 6 of 34
patients (18%) developed some degree of AKI
(patients 6-11 in the present study) [10]. Renal events
occurred within 3 months of transplantation, and no
late renal abnormalities were noted. Two patients
who required dialysis died because of complications
of hospitalization. A third patient required dialysis
for 21 months, and at 6 years posttransplantation was
dialysis-independent with a serum creatinine level of
2.4 mg/dL. Because of an apparent increased incidence
of AKI in the pilot U.S. autologous HCT trial com-
pared with the European study, kidney shielding
with a limitation to 200 cGy renal transmission was in-
stituted for the subsequent randomized SCOT trial.
Other measures adopted in the SCOT trial to mini-
mize nephrotoxicity include the routine administra-
tion of ACE-I through day 60 posttransplantation
(ie, through glucocorticoid therapy). Use of captopril
as an ACE-I is not recommended in HCT recipients,
because the sulfa moiety in this agent has been associ-
ated with neutropenia. Aggressive control of blood
pressure (to below 110/80 mm Hg), restricted use of
glucocorticoids, prohibition of i.v. contrast, and close
monitoring of renal function, including urinary pro-
tein/creatinine ratios, are also standard practice. It isnotable that to date, only 2 of the transplant recipients
in the SCOT trial have developed transient renal com-
plications after autologous HCT, and both of these
individuals are surviving with normal renal function.
As shown in Table 2, AKI can develop in patients
with SSc in the absence of HCT. The prevalence of
SRC in patients with SSc is estimated to be as high as
19% [1-3]. SRC is more common in individuals with
diffuse cutaneous scleroderma and is rare in patients
with limited disease. The majority of patients with
SRC present within 5-6 years of their initial diagnosis of
SSc and classically demonstrate malignant hypertension
(90% of patients), microangiopathic hemolytic anemia
(MAHA; 43%), and central nervous system abnor-
malities (11%). However, 10% of individuals with SRC
may present with normal blood pressure readings (so-
called ‘‘normotensive renal crisis’’) [23]. The etiology of
SRC is poorly understood, but renal vascular intimal
proliferation, vascular hyperreactivity, decreased cortical
blood flow, and activation of the renin–angiotensin–
aldosterone axis have all been implicated [24,25]. The
primary treatment of SRC is ACE-I therapy, given
even in the presence of AKI. With ACE-I admin-
istration, the 1-year mortality of SRC has decreased
dramatically from 76% to 15% [26,27]. Glucocorticoid
administration, particularly at high doses (ie, pred-
nisone $15 mg/day or equivalent), has been postulated
to trigger the onset of SRC [25,28]. However, in the
appropriate clinical setting (ie, Rodnan skin hardening
score $20 and large joint contractures), even lower
doses of prednisone (mean, 7.4 mg daily) have been
associated with SRC. Multivariate regression analysis
demonstrated that the nature clinical characteristics
was more important than prednisone use in predicting
the development of SRC [29,30]. Therefore, systemic
steroid use in patients with SSc requires careful renal
function and blood pressure monitoring. The use of
prophylactic ACE-I is controversial, but should be
considered in this particular clinical situation.
Patients undergoing allogeneic HCT appear to be
at increased risk for developing renal abnormalities be-
cause of administration of calcineurin inhibitors and
high-dose corticosteroids for the prevention or treat-
ment of GVHD [31]. Two patients with SSc who un-
derwent allogeneic HCT are included in the present
review. No significant renal complications were ob-
served during 7 months of cyclosporine treatment in
one patient. In the other patient (patient 5), SRC was
temporally associated with the administration of pred-
nisone 2 mg/kg/day. However, the patient died 18
months after allogeneic HCT because of complica-
tions of chronic GVHD while tolerating long-term
calcineurin inhibitor therapy without significant renal
dysfunction [11]. Based on this limited experience, it is
not possible to comment on the risk of renal dysfunc-
tion in SSc subjects receiving calcineurin inhibitor
therapy.
Table 3. Distinguishing between TTP and SRC*
Characteristic TTP SRC TA-TMA
Thrombocytopenia Yes Yes Yes
MAHA Yes Yes Yes
LDH Elevated Elevated Elevated
Peripheral smear Schistocytes Schistocytes Schistocytes
Bilirubin Elevated Elevated Elevated
Coombs test Negative Negative Negative
Neurologic dysfunction Yes Yes Yes
Hypertension Possible Yes Possible
Hemorrhagic manifestations Yes No Possible
Fever Yes No No
Acute renal impairment Yes Yes Yes
Thrombotic microangiopathy Yes Yes Yes
Coagulation profile Normal PT, PTT Normal PT, PTT Normal PT, PTT
Type of SSc Usually limited Usually diffuse NA
vWF-cleaving protease Low Not known Normal
Therapy Plasmapheresis ACE-I Supportive care
LDH indicates lactate dehydrogenase; PT, prothrombin time; PTT, activated partial thromboplastin time; NA, not applicable.
*Adapted from Manadan et al. 2005 [47].
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for patients withmalignant disease has been implicated
in the development of CKD, TA-TMA, hemolytic
uremic syndrome (HUS), and radiation nephritis
[8,32]. A recent study found a similar risk of
developing AKI after haploidentical allogeneic HCT
in groups that did and did not receive TBI in the
conditioning regimen; however, the TBI group was
more likely to develop CKD [8]. Clinical features of
HUS and TA-TMA may be indistinguishable from
those of radiation nephritis, which also may present
with hypertension, anemia, edema, proteinuria, hema-
turia, and elevated serum creatinine level [33,34].
Posttransplantation TTP or TA-TMA has been re-
ported in 0.51%-74% of patients undergoing alloge-
neic HCT [35-38] and in 0.13%-0.25% of those
undergoing autologous HCT [39]. TA-TMA appears
to be distinct from idiopathic TTP, given different
causative events and higher mortality [40]. TA-TMA
usually is not associated with deficiency of ADAMTS
13 (a disintegrin and metalloprotease with thrombo-
spondin type 1 motif, member 13) activity or with
the presence of inhibitory antibodies [41]. Moreover,
TA-TMA usually does not respond to plasma ex-
change [42]. The clinical distinctions among TA-
TMA, TTP, and normotensive SRC in the absence
of ADAMTS 13 determinations can be problematic;
for example, the clinical findings in patient 2 in our
series were attributed to normotensive SRC, but this
patient also was treated for TTPwith plasma exchange
and had a successful outcome.
In the setting of either SSc or HCT, AKI also may
result from the development of TTP. Classic TTP is
a relatively rare syndrome characterized by a pentad
of AKI, thrombocytopenia,MAHA, neurologic abnor-
malities, and fever. These signs and symptoms result
from microvascular platelet clumping [43,44]. Left
untreated, TTP is often rapidly fatal, whereas
prompt initiation of plasma exchange can belifesaving [45,46]. Several reports have noted the
coexistence of TTP with SSc [47-49]. True TTP in
individuals with SSc may mimic SRC, and radiation
nephritis, MAHA, and drug- induced nephrotoxicity
also may contribute to the differential diagnosis
of posttransplantation AKI. Features that help
distinguish TTP from SRC have been detailed by
Manadan et al. [47] and are summarized in Table 3.
Laboratory testing for ADAMTS-13 (von Wiilebrand
factor [vWF] cleaving protease) and the plasma con-
centration of ultra-large vWF multimers might pro-
vide additional clarifying information, but these tests
are not readily available in most institutions. There-
fore, whenever there is clinical suspicion of TTP,
treatment with plasma exchange should be initiated
promptly, because a delay can be life-threatening.
Plasma exchange can be discontinued if ADAMTS-
13 activity is normal.
HCT is an increasingly popular and possibly suc-
cessful treatment for selected patients with SSc and
other autoimmune diseases [50]. AKI in patients with
SSc undergoing HCT might be attributable to several
causes, making the diagnosis and management of these
patients particularly challenging. Renal shielding dur-
ing TBI, careful blood pressure control, avoidance of
i.v. contrast dyes or high-dose glucocorticoids, and ag-
gressive ACE-I therapy may reduce the development
of AKI in patients with SSc undergoing autologous
or allogeneic HCT. The decrease in AKI should re-
duce the posttransplantation mortality and the burden
of CKD following transplantation.ACKNOWLEDGMENTS
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